Compare Carparts.Com Inc (PRTS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Carparts.Com Inc trades at $10.2 (market cap $72.26M), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 1855.2× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| PRTS | VRTX | |
|---|---|---|
Market Cap | $72.26M | $134.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $557.96 |
52-Week Low | $3.88 | $376.62 |
Enterprise Value | $85.23M | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarParts.com (PRTS) trades at $9.50, up 2.15% with strong technical momentum and bullish moving average signals. The company shows improving quarterly earnings performance with three consecutive beats, though it remains unprofitable with negative margins. Recent developments include a new $25 million credit facility and Nasdaq compliance restoration, while analyst sentiment leans positive with 60% buy ratings.
The outlook suggests cautious optimism given improving earnings trajectory and technical strength, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investment appeal hinges on the company's ability to translate revenue stabilization into profitability while managing operational challenges in the automotive e-commerce sector.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
